Joseph Echevarria - Pfizer Independent Director

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:3em;padding-top: 38px;;'>PFE</div>
PFE -- USA Stock  

Trending

  Director
Mr. Joseph J. Echevarria is an Independent Director of Pfizer Inc.. Mr. Echevarria was Chief Executive Officer of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporationrationration, Unum Group, a provider of financial protection benefits, and Xerox Corporationrationration. Member of the Presidents Export Council and former member of the Presidential Commission on Election Administration. Chair Emeritus of My Brothers Keeper Alliance. Member of the Board of Trustees of the University of Miami. Mr. Echevarrias 36year career at Deloitte brings financial expertise and international business, leadership and risk management skills to the Board. Mr. Echevarrias financial acumen, including his significant previous audit experience, expertise in accounting issues and service on the audit committee of another public company, is an asset to Pfizers Board and Audit Committee. Pfizer also benefits from Mr. Echevarrias breadth and diversity of experience, which includes his public service on the Presidents Export Council.
Age: 62  Director Since 2015      
212 733-2323  www.pfizer.com
Echevarria was Chief Executive Officer of Deloitte LLP, a global provider of professional services, from 2011 until his retirement in 2014. During his 36year tenure with Deloitte, served in various leadership roles, including Deputy Managing Partner, Southeast Region Audit Managing Partner and U.S. Managing Partner and Chief Operating Officer. Director of The Bank of New York Mellon Corporationrationrationration, Unum Group, a provider of financial protection benefits, and Xerox Corporationrationrationration. Member of the President?s Export Council and former member of the Presidential Commission on Election Administration. Chair Emeritus of My Brother?s Keeper Alliance. Member of the Board of Trustees of the University of Miami.

Joseph Echevarria Latest Insider Activity

Pfizer Management Efficiency

Pfizer Inc has Return on Asset of 8.0E-4 % which means that on every $100 spent on asset it made $8.0E-4 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.2094 % implying that it generated $0.2094 on every 100 dollars invested. Pfizer management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 11.02, whereas Return on Average Assets are expected to decline to 8.28. Pfizer Tax Assets are expected to significantly decrease based on the last few years of reporting. The last year's Tax Assets were at 5.44 Billion. The current year Revenue to Assets is expected to grow to 0.35, whereas Assets Non Current are expected to decline to about 124.2 B. Pfizer Tax Liabilities is expected to significantly decrease based on the last few years of reporting. The last year's Tax Liabilities was at 18.68 Billion
The company has 47.96 B in debt with debt to equity (D/E) ratio of 80.0 . This implies that the company may be unable to create cash to meet all of its financial commitments. Pfizer Inc has Current Ratio of 1.44 which is typical for the industry and considered as normal.

Similar Executives

Showing few of many executives

DIRECTOR Since

Bruce SachsVertex Pharmaceuticals Incorpor
2017
Theodore SamuelsPerrigo Company Plc
2017
Louise ParentZoetis Inc
2013
Robert ScullyZoetis Inc
2013
Kalpana MorpariaDr Reddys Laboratories
2007
Theodore SamuelstoPerrigo Company Plc
2017
Laurie BrlasPerrigo Company Plc
2016
Alan GarberVertex Pharmaceuticals Incorpor
2017
Michael BrownRegeneron Pharmaceuticals
1991
Bradley AlfordPerrigo Company Plc
2017
Paul BisaroZoetis Inc
2015
Marc TessierLavigneRegeneron Pharmaceuticals
2011
Huda ZoghbiRegeneron Pharmaceuticals
2016
Sangeeta BhatiaVertex Pharmaceuticals Incorpor
2015
Allan ObermanDr Reddys Laboratories
2019
William DoyleZoetis Inc
2015
Bruce CarterDr Reddys Laboratories
2008
Jacqualyn FousePerrigo Company Plc
2012
Anthony ColesRegeneron Pharmaceuticals
2017
J MoreauDr Reddys Laboratories
2007
Bharat DoshiDr Reddys Laboratories
2016

Company Summary

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 88300 people.Pfizer Inc (PFE) is traded on BATS Exchange in USA and employs 88,300 people.

Pfizer Inc Leadership Team

John Young, Group President - Pfizer Innovative Health and Angela Hwang
Jennifer Damico, Senior Vice President Principal Accounting Officer, Controller
Frank DAmelio, Chief Financial Officer, Executive Vice President - Business Operations and Global Supply
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Lead Independent Director
James Smith, Independent Director
Dennis Ausiello, Independent Director
Mikael Dolsten, Chief Scientific Officer, President - Worldwide Research, Development and Medical
Susan DesmondHellmann, Director
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President, Chief Technology Officer and Digital Officer
Gordon Loh, Senior Vice President Corporate Audit
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
Alexander Mackenzie, Executive Vice President Chief Development Officer
Geno Germano, Group President of Global Innovative Pharma Bus.
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Chief Corporate Affairs Officer, Executive Vice President
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Susan Hockfield, Independent Director
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Chief Compliance, Quality and Risk Officer, Executive Vice President
Dan Littman, Independent Director
Ian Read, Chairman, CEO and Chairman of Executive Committee
James Kilts, Independent Director
Don Cornwell, Independent Director
James Quincey, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Independent Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President, Pfizer Biopharmaceuticals Group
Scott Gottlieb, Independent Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Stock Performance Indicators

Did you try this?

Run Commodity Channel Index Now

   

Commodity Channel Index

Use Commodity Channel Index to analyze current equity momentum
All  Next Launch Module

Currently Active Assets on Macroaxis

F   
Purchased over 500 shares of
3 hours ago
Traded for 5.9
SNE   
Purchased over 40 shares of
3 hours ago
Traded for 66.75
GOOG   
Purchased few shares of
3 hours ago
Traded for 1439.22
VMW   
Purchased a lot of shares of
3 hours ago
Traded for 152.94
V   
Purchased few shares of
3 hours ago
Traded for 196.36
Please check Your Equity Center. Please also try Money Managers module to screen money managers from public funds and etfs managed around the world.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page